Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antazoline + naphazoline (Amman Pharmaceutical Industries)
- Development stage
- Unknown
- Lead developer
- Amman Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Intranasal, Ophthalmic
01
Overview
Dott Allergy Eyes is an over-the-counter (OTC) dual-action ophthalmic and nasal formulation developed by Amman Pharmaceutical Industries under its Apisal product line. It combines the first-generation antihistamine antazoline with the sympathomimetic decongestant naphazoline. Antazoline acts as a selective histamine H1 receptor antagonist to alleviate ocular itching, watering, and allergic rhinitis symptoms. Naphazoline acts as an alpha-adrenergic receptor agonist, constricting conjunctival and nasal mucosal blood vessels to rapidly reduce redness, congestion, and swelling. Dott Allergy Eyes is approved and marketed for the temporary relief of allergic conjunctivitis and associated eye and nasal allergy symptoms.
- Brand names
- Dott Allergy E/DDott Allergy EyesDott Allergy Eyes and Nose DropDott Allergy Eyes and Nose DropsOphtazolinVasocon-A
- Other names
- antazoline hydrochloride + naphazoline hydrochlorideantazoline phosphate + naphazoline hydrochlorideantazoline/naphazolinenaphazoline + antazolinenaphazoline/antazoline
02
Targets
HRH1 (Histamine H1 Receptor)ADRA1A (α1A)HRH2 (Histamine H2 Receptor)ADRA2A (α2A)HRH3 (Histamine Receptor H3)
Beyond the preview
Go deeper on antazoline + naphazoline (Amman Pharmaceutical Industries).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antazoline + naphazoline (Amman Pharmaceutical Industries).